Sandra Ortiz-Cuaran· @SandraOrtizCua1 · X·· 8 小时前评分70
正文 · 机器翻译
DeLLphi-305 在 ES-#SCLC 中取得了令人瞩目的成果。
💊Tarlatamab + durvalumab vs durvalumab 维持治疗
- 中位 OS：21.1 vs 12.7 个月
- 12 个月 OS：79% vs 53%
在 #ESMO26 上获得全场起立鼓掌，同时在 @NEJM 发表。
恭喜 M. Pérol @MP_3855！
@CLCCLeonBerard
11 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgPresented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO在 X 查看被引用的帖子
来源：Sandra Ortiz-Cuaran · x.com